Estrogen Protects Against Growth Hormone's Own Negative Feedback in Postmenopausal Women

Short-term estradiol replacement in postmenopausal women selectively blocked GH's autonegative feedback on GHRP-2-stimulated secretion, explaining women's higher GH output and supporting sex-specific GH therapy approaches.

Anderson, S M et al.·The Journal of clinical endocrinology and metabolism·2001·Moderate EvidenceRCT
RPEP-00643RCTModerate Evidence2001RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Estradiol replacement selectively relieved GH autonegative feedback on GHRP-2-stimulated (not GHRH-stimulated) GH secretion in postmenopausal women, demonstrating pathway-specific estrogen modulation of the somatotropic axis.

Key Numbers

How They Did This

RCT in postmenopausal women. Short-term oral estradiol vs placebo. GH feedback tested by pre-infusing GH before GHRP-2 or GHRH stimulation. 10-minute blood sampling with GH deconvolution analysis.

Why This Research Matters

Understanding how estrogen modulates GH feedback is essential for optimizing GH secretagogue therapy in women — particularly postmenopausal women who are most likely to need GH enhancement.

The Bigger Picture

Sex hormones profoundly influence the GH axis. This precision — estrogen protecting one GH pathway but not another — reveals the sophisticated interaction between reproductive and somatotropic endocrine systems.

What This Study Doesn't Tell Us

Small sample inherent to intensive neuroendocrine studies. Oral estradiol (first-pass liver effects) may differ from transdermal. Short-term estrogen may not reflect chronic use.

Questions This Raises

  • ?Does transdermal estradiol have the same GHRP-2 protective effect?
  • ?Should postmenopausal women on GH secretagogues also receive estrogen?
  • ?Does this explain menopause-related GH decline?

Trust & Context

Key Stat:
Pathway-specific Estrogen protected GHRP-2-stimulated GH from feedback inhibition but did NOT protect GHRH-stimulated GH — exquisite pathway selectivity
Evidence Grade:
Moderate evidence from a mechanistic RCT with intensive hormonal profiling in the relevant clinical population.
Study Age:
Published in 2001. The estrogen-GH axis interaction continues to inform GH secretagogue prescribing in women.
Original Title:
E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.
Published In:
The Journal of clinical endocrinology and metabolism, 86(12), 5904-11 (2001)
Database ID:
RPEP-00643

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Does estrogen affect how GH peptides work?

Yes. This study shows estrogen specifically protects the GHRP-2 pathway from GH's self-inhibition. Postmenopausal women (low estrogen) may get less benefit from GHRP-2 unless estrogen is supplemented.

Should women on menopause hormones also take GH peptides?

This study suggests the combination could be beneficial — estrogen enhances GHRP-2's effectiveness by removing a negative feedback brake. However, clinical decisions should be made with a physician.

Read More on RethinkPeptides

Cite This Study

RPEP-00643·https://rethinkpeptides.com/research/RPEP-00643

APA

Anderson, S M; Wideman, L; Patrie, J T; Weltman, A; Bowers, C Y; Veldhuis, J D. (2001). E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.. The Journal of clinical endocrinology and metabolism, 86(12), 5904-11.

MLA

Anderson, S M, et al. "E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.." The Journal of clinical endocrinology and metabolism, 2001.

RethinkPeptides

RethinkPeptides Research Database. "E2 supplementation selectively relieves GH's autonegative fe..." RPEP-00643. Retrieved from https://rethinkpeptides.com/research/anderson-2001-e2-supplementation-selectively-relieves

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.